Trump FDA Commissioner Marty Makary out
Dr. Marty Makary is out as FDA commissioner, President Donald Trump said Tuesday, ending a controversial tenure at the health agency.
Makary is “a wonderful man and he’s going to be off, and the assistant, the deputy, is taking over temporarily,” Trump told reporters on Tuesday.
He added, “He’s going to go on, and he’s going to lead a good life.”
Several news outlets reported that Makary resigned on Tuesday, which followed days of reporting that the White House was planning to fire him.
Kyle Diamantas, who previously worked as the top food official at the FDA, will step in as acting commissioner, according to reports. Trump on Tuesday did not name Diamantas.
Makary, a surgical oncologist known for criticizing the government’s handling of the Covid pandemic, had reportedly fallen out of favor with both FDA staff and the White House in recent months. He served as head of the agency responsible for regulating food, drugs and medical devices for more than a year.
His tenure was marked by internal dysfunction and leadership turmoil at the FDA, along with mounting backlash from drugmakers, physicians and patient groups on regulatory decisions, including high-profile rejections of some rare disease treatments. At the same time, the White House reportedly grew increasingly impatient with what it viewed as his slow movement on Trump’s key policy initiatives, such as legalizing flavored vapes.
Makary has touted his accomplishments as commissioner, including his priority voucher program that accelerates review times for certain drugs.
But staff morale at the agency plummeted after layoffs and departures of career agency scientists, including longtime cancer regulator Dr. Richard Pazdur, who cited Makary’s leadership as his reason for leaving. Meanwhile, distrust of leadership has reportedly grown among the staff that remained.
Among Makary’s most polarizing appointees was Vinay Prasad, who served as a key agency official overseeing vaccines and biotech treatments before stepping down at the end of April. Prasad, an outspoken academic and podcaster, left the agency after mounting criticism of the FDA within the biotech and pharmaceutical industries and among former health officials.
For example, the FDA initially refused to review Moderna’s flu shot – a decision that the biotech company said was inconsistent with previous agency guidance and specifically stemmed from Prasad. The FDA later reversed course on the vaccine.
Prasad also faced backlash earlier this year for his rejection of a Huntington’s disease gene therapy from uniQure, which claimed the FDA was requiring it to perform fake brain surgery to evaluate whether the treatment works. In a CNBC interview in March, Makary appeared to criticize that treatment without naming it.
In April, the FDA rejected Replimune’s drug candidate for melanoma a second time after an initial rejection in July. The agency cited insufficient evidence of effectiveness and took issue with the single-arm trial design.
In an interview with CNBC in May, Makary said three independent teams have arrived at the same conclusion around the drug and that the FDA has not made “corrupt sweetheart deals.”
“I don’t work for Replimune, I work for the American people, and I stand by the scientists at the FDA,” Makary said in the interview with CNBC’s David Faber.
In March, Sen. Ron Johnson, R-Wisc., announced an investigation into the FDA’s rejection of rare disease treatments.
<
